Importantly, PCNS-DLBCL patients with BCL-2 and C-MYC coexpression had a 0% 5-year PFS rate, whereas patients with BCL or C-MYC expression had a 20% rate. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.